StockMarketWire.com - Tiziana Life Sciences said an independent analysis has concluded that treatment with cancer drug Milciclib was safe and well-tolerated.

A monitoring committee conducted interim analysis of the drug's safety on six patients, finding that it had no adverse events in patients with unresectable or metastatic hepatocellular carcinoma.

Another trial to evaluate safety and clinical activity of Milciclib in combination with sorafenib was expected to start in the second quarter of 2018, the company said.

"Unresectable or metastatic HCC is an aggressive type of liver cancer for which no satisfactory treatment is currently available," chairman Gabriele Cerrone said.

"The establishment of Milciclib's safety is a significant milestone as it paves way to move forward with clinical studies evaluating Milciclib in combination with sorafenib or nivolumab for treatment of HCC."




Story provided by StockMarketWire.com